ExpreS2ion and University of Bologna announce research collaboration to test HER2-cVLP in state-of-the-art breast cancer mice models

Report this content

Hørsholm, Denmark, February 23, 2021 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") and the University of Bologna (“UniBo”) announce a research collaboration agreement (“Agreement”) which covers testing of the novel HER2-cVLP breast cancer vaccine program, including the selected lead candidate ES2B-C001, in proprietary state-of-the-art breast cancer mice models. The collaboration follows the recently presented in-licensing of the HER2-cVLP technology from AdaptVac. The outcome of the collaboration is expected to support ExpreS2ion’s breast cancer vaccine project and will constitute a proof of preclinical concept. The research collaboration is budgeted and planned for within the proceeds from the recent rights issue.

ExpreS2ion, with the expert assistance of Prof. Pier Luigi Lollini at the Interdepartmental Center for Cancer Research, University of Bologna, will soon start the selection process for the lead candidate ES2B-C001, exploiting state-of-the-art in vitro and in vivo models mimicking some of the mechanisms in human breast cancer.

CEO Bent Frandsen comments:

“We are excited to include the studies by Prof. Lollini into our overall development program of ES2B-C001. This grants us access to excellent know-how on the conduct of the most optimal preclinical PoC studies.”

Prof. Pier Luigi Lollini comments:

“I am pleased to continue the collaboration on the HER2-cVLP cancer vaccine candidates, thus increasing our knowledge on the potential effects of therapeutic cancer vaccination.”

About the ES2B-C001 breast cancer vaccine candidate

ExpreS2ion is engaged in the development of the innovative ES2B-C001 HER2 breast cancer vaccine based on the unique capsid virus-like particle (cVLP) technology. ExpreS2ion recently in-licensed the project from its joint venture company AdaptVac, thus securing full control of the further development of ES2B-C001 and an exclusive global commercial license. Virus-like particle-based cancer vaccines are highly immunogenic due to sharing key characteristics with live viruses. ES2B-C001 is therefore expected to elicit an immune response in HER2-breast cancer patients that will lead to a substantial therapeutic effect.

About UniBo and Prof. Lollini

Founded in 1088, the University of Bologna is the oldest university in the world and it has been student-centered whilst attracting prominent figures from science and the arts. It is one of the most prestigious Italian universities, commonly ranking in the first places of national, European, and international rankings both as a whole and for individual subjects. Dr. Pier Luigi Lollini is Professor in General Pathology and a member of the Interdepartmental Center for Cancer Research directed by Prof. Andrea Pession. Prof. Lollini’s interests fall within tumor immunology, the metastatic process and the molecular biology of breast cancer. Prof. Lollini, a Member of the European Academy of Tumor Immunology (EATI), has published more than 200 scientific papers, and is recognized for his preclinical research efforts for breast cancer immunoprevention and immunotherapy.

Certified Adviser

Svensk Kapitalmarknadsgranskning AB

Telefon: +46 11 32 30 732

E-post: ca@skmg.se


This press release constitutes inside information that ExpreS2ion Biotech Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was sent for publication, through the agency of the contact persons set out above, at the time stated by the Company’s news distributor, Cision, at the publication of this press release.

For further information about ExpreS2ion Biotech Holding AB, please contact:

Bent U. Frandsen, CEO
Telephone: +45 4256 6869

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 300 proteins and 40 virus-like particles (VLPs) in collaboration with leading research institutions and companies. Since 2017, ExpreS2ion develops novel capsid VLP based vaccines through its joint venture AdaptVac ApS. For additional information, please visit www.expres2ionbio.com and www.adaptvac.com.